Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 study of RLYB116 in healthy participants completed, reporting safety, tolerability, and pharmacokinetic/pharmacodynamic data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Diseases
• Hematologic Diseases

Drugs mentioned

• RLYB116

Snippet

Sponsor: Rallybio | Conditions: Hematologic Diseases, Autoimmune Diseases | Phase 1 | Status: COMPLETED